SpinaFX Earns CE Mark for Triojection Spine System
TORONTO, July 16, 2026 SpinaFX Medical Inc. has achieved a significant regulatory milestone with the Medical Device Regulation (MDR)...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TORONTO, July 16, 2026 SpinaFX Medical Inc. has achieved a significant regulatory milestone with the Medical Device Regulation (MDR)...
BOCA RATON, Fla., June 2026 SurGenTec® has announced U.S. FDA clearance for its ION-L™ Lumbar Facet Fixation System, a...
TORONTO, June 9, 2026 SpinaFX Medical has achieved a major regulatory milestone after receiving U.S. Food and Drug Administration...
